Bioequivalence Study of Dapagliflozin 10 mg Tablets in Healthy Volunteers Under Fasting Conditions for Diabetes Management

The primary objective of this study is to evaluate the **bioequivalence** of dapagliflozin 10 mg tablets following a single oral dose administration in healthy volunteers under fasting conditions. This is clinically relevant as establishing bioequivalence ensures that the generic formulation of dapagliflozin is therapeutically equivalent to the reference product, which is crucial for maintaining consistent efficacy and safety in the management of **diabetes**. No secondary objectives are provided in the available data.

The clinical trial involves participants diagnosed with **Diabetes**. The study population includes both male and female subjects, with an age range category code of 3, which typically corresponds to adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria, including any lifestyle considerations such as diet or physical activity, have not been disclosed. The trial population was selected without specific emphasis on vulnerable groups, ensuring a broad representation of individuals with the condition under investigation.

The clinical trial is designed to evaluate the **bioequivalence** of dapagliflozin 10 mg tablets following a single oral dose administration to healthy volunteers under fasting conditions. This study is a Phase 2 trial, which is categorized as a randomized, double-blind, controlled trial. The estimated recruitment start date is September 16, 2024, with an anticipated end date of October 21, 2024. The trial will involve a sequence of study visits, beginning with an inclusion visit where participants will undergo screening to ensure they meet the eligibility criteria. This will be followed by the administration of the investigational product and subsequent follow-up visits to monitor the participants' health and collect necessary data. The end-of-study visit will conclude the trial, where final assessments will be conducted to evaluate the outcomes.

Participants are expected to be involved in the study for the duration of the trial, from the initial screening through to the end-of-study visit. Conditions that may lead to early termination from the study include adverse reactions to the investigational product, non-compliance with study procedures, or withdrawal of consent by the participant. The trial aims to provide valuable data on the bioequivalence of dapagliflozin, contributing to the understanding of its pharmacokinetic profile in healthy individuals. The study is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included in the provided dataset. As such, these aspects cannot be detailed in the context of this clinical trial description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 2 study, which typically focuses on assessing the efficacy of a treatment in a specific patient population. The trial is scheduled to commence recruitment on September 16, 2024, with an estimated end date of October 21, 2024. Although specific efficacy parameters or endpoints are not detailed, Phase 2 trials generally involve the use of validated scales, laboratory tests, or patient-reported outcomes to measure treatment effects. The collection and analysis of efficacy data are expected to follow a predefined schedule, aligning with standard practices in clinical research. The trial's design will ensure that efficacy assessments are conducted systematically to provide reliable and scientifically valid results.